| Placebo | HMW-HA (Yabro®) | p-value |
---|---|---|---|
Demographics | Â | Â | Â |
 N | 21 | 20 |  |
 Age | 74.2 ± 10 | 77.4 ± 8.5 | 0.85 |
 Male (%) | 35 | 35 | 1.00 |
Medical History (% of patients with history) | Â | Â | Â |
 Home O2 therapy | 57 | 55 | 1.00 |
 COPD exacerbation requiring hospitalization in past year | 43 | 30 | 0.52 |
 Home NIV use | 19 | 15 | 1.00 |
 Coronary Artery Disease | 57 | 60 | 0.85 |
 Neurovascular Disease | 9.5 | 25 | 0.19 |
 Chronic Kidney Disease | 19 | 25 | 0.64 |
 Diabetes | 29 | 40 | 0.44 |
 Hypertension | 62 | 85 | 0.09 |
 Past Pneumonia | 38 | 25 | 0.37 |
 Peptic Ulcer Disease | 0 | 15 | 0.06 |
 IADL Score | 4.9 ± 2.6 | 4.7 ± 2.0 | 0.83 |
Admission Vital Signs | Â | Â | Â |
 Mean arterial pressure (mmHg) | 89 ± 9 | 87 ± 12 | 0.70 |
 Heart Rate (per minute) | 75 ± 10 | 81 ± 11 | 0.10 |
 Respiratory Rate (per minute) | 27 ± 5 | 27 ± 4 | 0.73 |
 Temperature (°C) | 36.0 ± 0.4 | 35.9 ± 0.5 | 0.47 |
 Body Mass Index | 26.9 ± 8.6 | 24.7 ± 5.7 | 0.50 |
Admission Respiratory Parameters | Â | Â | Â |
 FiO2 (%) | 27 ± 8 | 29 ± 7 | 0.38 |
 PaO2 (mmHg) | 62 ± 12 | 60 ± 15 | 0.59 |
 PaCO2 (mmHg) | 66 ± 13 | 63 ± 9 | 0.40 |
 pH | 7.34 ± 0.04 | 7.34 ± 0.04 | 0.95 |
 IPAP | 16.1 ± 3.4 | 16.3 ± 3.8 | 0.70 |
 PEEP | 6.1 ± 1.1 | 5.5 ± 0.7 | 0.10 |
Admission Laboratory Values | Â | Â | Â |
 Na (mEq/L) | 138 ± 3 | 139 ± 3 | 0.96 |
 K (mEq/L) | 4.1 ± 0.4 | 4.0 ± 0.5 | 0.21 |
 Creatinine (mg/dL) | 1.0 ± 0.5 | 1.0 ± 0.6 | 0.96 |
 Hematocrit (%) | 40.2 ± 6.4 | 39.8 ± 12.1 | 0.90 |
 WBC (× 1,000 cells/µL) | 10.2 ± 4.2 | 9.8 ± 3.9 | 0.74 |
 APACHE II score | 14.9 ± 2.7 | 14.7 ± 3.7 | 0.85 |
 Positive sputum culture | 4/21# | 3/20* | 1.00 |